Yeah, that's despite the impressive responses from PTX200 trials. As SYC explains, the landscape has changed in that there has been a lot of new therapies come to market for AML sufferers in the time that PTX200 has progressed through various trials. It sounds like with the last of the recruitments achieved, the trial will be concluded mid-year (if I'm not mistaken).
Its fair to say that perhaps PTX200 served its purpose in light of both CellPryme and OmniCAR. Some of the science behind CellPryme is derived from the AKT pathway inhibiiton technology (as highlighted by Hottod). And, one of our OmniCAR trials due to commence clinical trials sometime this year will be targeting AML (the same cancer type as PTX200's targeted therapy), so it makes sense to focus funds and energy on that AML trial now. But, to "farm it out" would be perfect.
PTX Media related, page-1065
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
-0.002(4.26%) |
Mkt cap ! $37.85M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.5¢ | $38.05K | 814.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 275279 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 29784 | 2 |
View Market Depth
| Last trade - 15.45pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.6¢ |
Change
-0.002 ( 2.13 %) |
||||
| Open | High | Low | Volume | ||
| 4.7¢ | 4.7¢ | 4.6¢ | 428792 | ||
| Last updated 14.48pm 21/05/2024 ? | |||||
| PTX (ASX) Chart |